IL122261A - Fluorocarbons Liquids for the treatment of conditions caused by a deficiency in the endogenous level of nitric oxide - Google Patents
Fluorocarbons Liquids for the treatment of conditions caused by a deficiency in the endogenous level of nitric oxideInfo
- Publication number
- IL122261A IL122261A IL12226196A IL12226196A IL122261A IL 122261 A IL122261 A IL 122261A IL 12226196 A IL12226196 A IL 12226196A IL 12226196 A IL12226196 A IL 12226196A IL 122261 A IL122261 A IL 122261A
- Authority
- IL
- Israel
- Prior art keywords
- nitric oxide
- fluorocarbon
- effective amount
- fluorocarbon emulsion
- emulsion
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 215
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 239000007788 liquid Substances 0.000 title claims abstract description 25
- 239000000839 emulsion Substances 0.000 title claims description 90
- 230000007812 deficiency Effects 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title description 6
- 238000001990 intravenous administration Methods 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 108010054147 Hemoglobins Proteins 0.000 claims description 26
- 102000001554 Hemoglobins Human genes 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 230000024883 vasodilation Effects 0.000 claims description 13
- 230000009849 deactivation Effects 0.000 claims description 7
- 230000002685 pulmonary effect Effects 0.000 claims description 7
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 229960001217 perflubron Drugs 0.000 claims description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 239000007789 gas Substances 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 241000238366 Cephalopoda Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 241000252073 Anguilliformes Species 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000008327 renal blood flow Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 229940123921 Nitric oxide synthase inhibitor Drugs 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000020673 hypertrichosis-acromegaloid facial appearance syndrome Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- -1 mannrtol or sorbitol Chemical compound 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000000520 progressive familial heart block Diseases 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/501,976 US5726209A (en) | 1995-06-07 | 1995-06-07 | Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir |
| PCT/US1996/009549 WO1996040058A2 (en) | 1995-06-07 | 1996-06-07 | Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL122261A0 IL122261A0 (en) | 1998-04-05 |
| IL122261A true IL122261A (en) | 2001-09-13 |
Family
ID=23995789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12226196A IL122261A (en) | 1995-06-07 | 1996-06-07 | Fluorocarbons Liquids for the treatment of conditions caused by a deficiency in the endogenous level of nitric oxide |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5726209A (no) |
| EP (1) | EP0831776A2 (no) |
| JP (1) | JPH11507351A (no) |
| KR (1) | KR19990022586A (no) |
| CN (1) | CN1192136A (no) |
| AU (1) | AU718120B2 (no) |
| CA (1) | CA2221965A1 (no) |
| HU (1) | HUP9900900A2 (no) |
| IL (1) | IL122261A (no) |
| NO (1) | NO975322L (no) |
| PL (1) | PL323821A1 (no) |
| WO (1) | WO1996040058A2 (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869539A (en) * | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| US6103275A (en) * | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
| RU2161122C1 (ru) * | 1999-09-10 | 2000-12-27 | Институт молекулярной генетики РАН | Способ ускорения окисления оксида азота (no) в гетерогенной среде |
| JP5781727B2 (ja) * | 2007-02-23 | 2015-09-24 | 株式会社ネクスト２１ | 血管攣縮の治療剤又は予防剤 |
| US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| US8618056B2 (en) | 2007-12-22 | 2013-12-31 | Cuthbert O. Simpkins | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| US20100196461A1 (en) * | 2009-01-30 | 2010-08-05 | Simpkins Cuthbert O | Resuscitation fluid |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
| US4865836A (en) * | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
| US4927623A (en) * | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
| US4781676A (en) * | 1987-02-20 | 1988-11-01 | Air Products And Chemicals, Inc. | Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells |
| US4866096A (en) * | 1987-03-20 | 1989-09-12 | Air Products And Chemicals, Inc. | Stable fluorochemical aqueous emulsions |
| US4895876A (en) * | 1987-03-20 | 1990-01-23 | Air Products And Chemicals, Inc. | Concentrated stable fluorochemical aqueous emulsions containing triglycerides |
| US4993415A (en) * | 1988-08-19 | 1991-02-19 | Alliance Pharmaceutical Corp. | Magnetic resonance imaging with perfluorocarbon hydrides |
| US5536241A (en) * | 1990-12-05 | 1996-07-16 | The General Hospital Corporation | Methods and devices for relaxing smooth muscle contractions |
| WO1993002653A1 (en) * | 1991-08-08 | 1993-02-18 | Segel Leigh D | Fluorocarbon blood substitute |
| US5628930A (en) * | 1992-10-27 | 1997-05-13 | Alliance Pharmaceutical Corp. | Stabilization of fluorocarbon emulsions |
| DE69425331D1 (de) * | 1993-10-08 | 2000-08-24 | Us Health | Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen |
| DE69424560T2 (de) * | 1993-11-02 | 2001-01-18 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, Baton Rouge | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden |
-
1995
- 1995-06-07 US US08/501,976 patent/US5726209A/en not_active Expired - Fee Related
-
1996
- 1996-06-07 PL PL96323821A patent/PL323821A1/xx unknown
- 1996-06-07 IL IL12226196A patent/IL122261A/en not_active IP Right Cessation
- 1996-06-07 AU AU61615/96A patent/AU718120B2/en not_active Ceased
- 1996-06-07 JP JP9501847A patent/JPH11507351A/ja active Pending
- 1996-06-07 HU HU9900900A patent/HUP9900900A2/hu unknown
- 1996-06-07 KR KR1019970709067A patent/KR19990022586A/ko not_active Application Discontinuation
- 1996-06-07 CN CN96195948A patent/CN1192136A/zh active Pending
- 1996-06-07 EP EP96919220A patent/EP0831776A2/en not_active Ceased
- 1996-06-07 WO PCT/US1996/009549 patent/WO1996040058A2/en active Search and Examination
- 1996-06-07 CA CA002221965A patent/CA2221965A1/en not_active Abandoned
-
1997
- 1997-11-19 NO NO975322A patent/NO975322L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9900900A2 (hu) | 1999-08-30 |
| MX9709695A (es) | 1998-06-28 |
| EP0831776A2 (en) | 1998-04-01 |
| WO1996040058A2 (en) | 1996-12-19 |
| PL323821A1 (en) | 1998-04-27 |
| US5726209A (en) | 1998-03-10 |
| JPH11507351A (ja) | 1999-06-29 |
| AU718120B2 (en) | 2000-04-06 |
| KR19990022586A (ko) | 1999-03-25 |
| NO975322D0 (no) | 1997-11-19 |
| CA2221965A1 (en) | 1996-12-19 |
| NO975322L (no) | 1998-01-09 |
| IL122261A0 (en) | 1998-04-05 |
| AU6161596A (en) | 1996-12-30 |
| WO1996040058A3 (en) | 1997-02-13 |
| CN1192136A (zh) | 1998-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2132043T3 (es) | Dispositivos para tratar vasoconstriccion pulmonar y asma. | |
| US6197323B1 (en) | Medicinal preparation containing a lipophilic inert gas | |
| US4927623A (en) | Dissolution of gas in a fluorocarbon liquid | |
| US20150231177A1 (en) | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | |
| EP0480925B1 (en) | Fluorocarbon emulsions having saturated phospholipid emulsifiers | |
| US5869538A (en) | Method for enhancing transport of gases to tissues | |
| US5726209A (en) | Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir | |
| US5874422A (en) | Use of non-steroidal anti-inflammatory agents to improve the physiological compatibility of particulate pharmaceutical preparations | |
| US6127428A (en) | Method for enhancing transport of gases to tissues | |
| Riess et al. | Update on perfluorocarbon-based oxygen delivery systems | |
| RU2162692C1 (ru) | Состав на основе эмульсии перфторорганических соединений для медико-биологических целей | |
| MXPA97009695A (en) | Liquid emulsion of fluorocarbon as vascular reserve of oxide nitr | |
| Faithfull | The role of perfluorochemicals in surgery and the ITU | |
| US20210100738A1 (en) | Oxygen delivery beverage | |
| JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
| JP3002486B2 (ja) | 飽和リン脂質乳化剤を含むフルオロカーボン乳剤 | |
| Flaim | Medical and therapeutic applications of perfluorocarbon-based products | |
| Spiess | Perfluorocarbon Emulsions: One Approach to Intravenous Artificial Respiratory Gas Transport | |
| Cabrales | Perfluorocarbon Emulsions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |